Aerosolized terbutaline sulfate in the treatment of bronchospasm.
Terbutaline sulfate, a relatively selective beta2 agonist, is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease. Studies have shown that when administered via an aerosol, terbutaline has a rapid onset, a prolonged duration of action, and a low incidence of systemic side effects. Because the drug is delivered directly to the bronchi, one can administer low doses of aerosolized terbutaline and achieve a bronchodilatory effect comparable to that achieved with higher doses of the oral form.
D000328:Adult; D000336:Aerosols; D000420:Albuterol / Q000627:therapeutic use; D001986:Bronchial Spasm / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000008:administration & dosage; D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D009921:Metaproterenol / Q000627:therapeutic use; D012138:Respiratory Therapy / Q000295:instrumentation; D013726:Terbutaline / Q000008:administration & dosage / Q000627:therapeutic use*; D013806:Theophylline / Q000008:administration & dosage; D013997:Time Factors
D000336:Aerosols; D004338:Drug Combinations; D009921:Metaproterenol; D013806:Theophylline; D007545:Isoproterenol; D013726:Terbutaline; D004205:Cromolyn Sodium; D000420:Albuterol